Core Points - Sempra Infrastructure and EQT Corporation have signed a 20-year sales and purchase agreement for the supply of 2 million tonnes per annum (Mtpa) of liquefied natural gas (LNG) from the Port Arthur LNG Phase 2 project [1][2] - The agreement is aimed at enhancing U.S. energy exports and supporting global energy security while promoting lower-carbon solutions [2] - The Port Arthur LNG Phase 2 project is expected to have a total liquefaction capacity of approximately 26 Mtpa, doubling the capacity from Phase 1 [5] Company Developments - Sempra Infrastructure has secured all major permits for the Port Arthur LNG Phase 2 project, including project approval from the Federal Energy Regulatory Commission and export authorization from the U.S. Department of Energy [3] - Bechtel has been selected for the engineering, procurement, and construction of the Port Arthur LNG Phase 2 facility, with a final investment decision targeted for 2025 [4] - The project has already attracted interest from other buyers, including a 20-year SPA with JERA Co., Inc. for 1.5 Mtpa and an expanded alliance with ConocoPhillips for 4 Mtpa [2] Industry Context - The Port Arthur LNG Phase 2 project is strategically positioned to meet global energy demand and is part of a broader effort to fortify America's role as a leading energy exporter [2] - The project aligns with the U.S. government's goals of enhancing energy security and supporting local economic development through natural gas projects [2]

Company Overview - Alignment Healthcare, Inc. is focused on providing high-quality, low-cost care for its Medicare Advantage members, emphasizing a mission-driven approach to senior care [2] - The company utilizes a customized care model, a 24/7 concierge care team, and proprietary technology named AVA to deliver coordinated care [2] Upcoming Events - Alignment Healthcare will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 8:30 a.m. EDT [3] - The company will also participate in the Baird 2025 Global Healthcare Conference on September 10, 2025, at 12:15 p.m. EDT [3] Corporate Values - Alignment Healthcare prioritizes its core values of serving with a heart and putting seniors first as it expands its national footprint [2]

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025 Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET 2025 Wells Fargo Healthcare ConferenceFireside chat on Friday, September 5, 2025, at 8:45 a ...

Core Insights - RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases [2] Group 1: Company Overview - RAPT Therapeutics specializes in discovering, developing, and commercializing novel therapies aimed at modulating immune responses related to inflammatory and immunological diseases [2] - The company leverages proprietary expertise in immunology to create innovative treatment options for patients [2] Group 2: Upcoming Events - RAPT management will participate in several investor conferences in September 2025, including: - 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ET [3] - Cantor Global Healthcare Conference on September 4, 2025, at 1:00 p.m. ET [3] - H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 9:00 a.m. ET [3] - Stifel 2025 Virtual Immunology & Inflammation Forum on September 15, 2025, at 9:30 a.m. ET [3] - Live webcasts and archived recordings of these events will be available on the RAPT Therapeutics website [1]

Company Overview - Axogen, Inc. (NASDAQ: AXGN) is a leader in developing and marketing surgical solutions aimed at restoring peripheral nerve function [3] - The company focuses on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair [3] - Axogen's mission is to help restore peripheral nerve function and improve the quality of life for patients with nerve damage through innovative and clinically proven solutions [3] Product Portfolio - Axogen's product offerings include: - **Avance Nerve Graft**: A processed human nerve allograft for bridging severed peripheral nerves [4] - **Axoguard Nerve Connector**: An extracellular matrix coaptation aid for tensionless repair of severed nerves [4] - **Axoguard Nerve Protector**: A product used to wrap and protect damaged nerves while minimizing soft tissue attachments [4] - **Axoguard HA+ Nerve Protector™**: A next-generation technology designed to enhance nerve gliding and provide protection for peripheral nerve injuries [4] - **Axoguard Nerve Cap**: A product to protect nerve ends and reduce the development of painful neuromas [4] - **Avive+ Soft Tissue Matrix™**: An amniotic membrane allograft used to protect and separate tissues during healing [4] - The product portfolio is available in multiple countries including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [4] Upcoming Investor Conferences - Axogen management is scheduled to participate in several investor conferences: - **Cantor Global Healthcare Conference**: Fireside chat on September 3, 2025 [1] - **Wells Fargo Healthcare Conference**: 1x1 investor meetings on September 4, 2025 [2] - **Morgan Stanley Annual Global Healthcare Conference**: 1x1 investor meetings on September 10, 2025 [2] - **Lake Street Best Ideas Growth (BIG 9) Conference**: 1x1 investor meetings on September 11, 2025 [2] - Webcast events will be accessible live and archived for 90 days on Axogen's investor page [2]

Core Viewpoint - Fusion Fuel Green PLC will release an Investor Update Presentation and Video on September 17, 2025, to provide updates on financial results and strategic developments [1][2]. Company Overview - Fusion Fuel Green PLC (NASDAQ: HTOO) specializes in integrated energy engineering, distribution, and green hydrogen solutions through its Al Shola Gas and BrightHy Solutions platforms [3]. - The company operates in the LPG supply and hydrogen solutions sectors, supporting decarbonization across industrial, residential, and commercial sectors [3]. - Fusion Fuel is headquartered in Ireland and has operations in Europe and the Middle East [3]. Upcoming Events - The Investor Update Presentation and Video will be available on the company's Investors page on its website [2]. - Management will discuss updates on the company's activities in Al Shola Gas and BrightHy Solutions, along with other strategic developments [2].

Core Viewpoint - GD Culture Group Limited is set to launch an AI Immersive Reading Platform that aims to revolutionize storytelling by making it interactive and personalized, allowing readers to shape narratives and engage with characters in new ways [1][2][4]. Group 1: Platform Features - The AI Immersive Reading Platform transforms traditional storytelling into an interactive experience, enabling readers to choose story directions, interact with characters, and personalize story elements [2]. - The platform offers AI-driven tools for creators, simplifying the writing process and facilitating the development of adaptive story scripts [3]. Group 2: Business Model and Community Engagement - Stories published on the platform will be available through a subscription model that shares revenue with creators, fostering a sustainable ecosystem for creativity [3]. - The company is building a community of creators to explore the future of storytelling, inviting storytellers, writers, and game designers to participate and gain early access to tools and resources [4]. Group 3: Company Overview - GD Culture Group Limited operates primarily through its subsidiaries, including AI Catalysis Corp, and plans to enter the livestreaming market focused on e-commerce [6].

Results reinforce telitacicept’s potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with I ...

Core Insights - DaVita Clinical Research (DCR) has been instrumental in advancing kidney care over the past 25 years, focusing on new therapies, clinical outcomes, and the future of nephrology through rigorous research and clinical trials [1][2][3] Research Contributions - DCR has authored 180 manuscripts and 520 research abstracts or posters aimed at improving clinical outcomes in kidney care and related diseases [4] - A 2017 study demonstrated that ClearGuard HD antimicrobial barrier caps significantly reduce bloodstream infections in dialysis patients, leading to improved outcomes [5] - Upcoming research will be presented at the American Society of Nephrology Kidney Week, highlighting the association between GLP-1 drugs and hospitalization rates for kidney failure patients [6] Clinical Trials and Innovations - DCR is the largest U.S. trial network for chronic kidney disease (CKD) and end-stage kidney disease (ESKD), conducting impactful trials efficiently [7] - DaVita contributed to COVID-19 vaccine trials and supported vaccination efforts for at-risk patients, showcasing its commitment to public health [8] - The company has implemented decentralized recruitment services to enhance diversity in clinical trials, addressing barriers faced by dialysis patients [9] Company Overview - As of June 30, 2025, DaVita served approximately 283,100 patients across 3,175 outpatient dialysis centers, with 2,662 centers in the U.S. and 513 in 13 other countries [11] - DaVita has conducted over 500 clinical trials across more than 250 research sites, engaging directly with every ESKD drug approved by the FDA [12]

PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences: Wells Fargo Healthcare Conference, Boston, MA: Fireside chat on Wednesday, September 3 at 9:30 am ETCantor Global Healthcare Conference – New York, NY: Fireside chat on Thursday, September 4 at ...